ChromaCode commercially launches HDPCR-based NSCLC assay

Date

Medical Device Network:

The assay leverages amplitude modulation and multi-spectral encoding to identify actionable NSCLC variants in nine relevant genes.

Genomics multiplexing platform company ChromaCode has commercially introduced the High Definition PCR (HDPCR)-based non-small-cell lung cancer (NSCLC) assay.

Leveraging amplitude modulation and multi-spectral encoding, the assay panel identifies actionable NSCLC variants in nine relevant genes from only low-sample input.

View full article

More Articles Here